Journal of Endocrinological Investigation

, Volume 34, Issue 3, pp 232–243 | Cite as

Androgen regulation of prostate cancer: Where are we now?

  • G. Corona
  • E. Baldi
  • M. Maggi
Review Article


Background: Androgens play an essential role in the development and differentiation of the prostate gland; their contribution to pathological conditions, such as benign prostatic hyperplasia and prostate cancer (PC), remains unclear. Aim: We reviewed relationships between androgens and the prostate both in physiological and pathological conditions. Material and methods: A systematic search of published evidence was performed using Medline (1969 to September 2010). Results: Androgen-dependency of prostate growth is evident only in the hypogonadal condition, but not in the eugonadal state (the “saturation hypothesis”). There is unequivocal evidence that reducing androgen signaling to the hypogonadal range can reduce PC growth and patient symptoms. At physiological testosterone concentration there is no link between androgen levels and PC risk. In addition, different strategies of androgen deprivation (ADT) for advanced PC are only palliative and rarely cure patients. Preliminary evidence indicates that a low androgen milieu is associated with tumor aggressiveness. Transition to androgen-independence is complex and involves both selection and outgrowth of preexisting androgen resistant clones, as well as adaptative upregulation of genes that help the cancer cells to survive and grow after ADT. Because androgens are essential for the regulation of fat distribution, insulin sensitivity, and lipid and bone metabolism, recent publications have highlighted the concept that ADT may also be involved with an increase in overall, as well as cardiovascular, morbidity and mortality. Conclusions: While ADT still represents a cornerstone for the palliative therapy of a small fraction of aggressive PC, a “misuse and/or abuse” of ADT should be avoided.


Androgen deprivation therapy cardiovascular risk osteoporosis prostate testosterone 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Fibbi B, Penna G, Morelli A, Adorini L, Maggi M. Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. Int J Androl 2010, 33: 475–88.PubMedGoogle Scholar
  2. 2.
    Isaacs JT. Testosterone and the prostate. In: Nieschlag E, Behre HM eds. Testosterone: action, deficiency, substitution 3rd ed. Cambridge: Cambridge University Press. 2004, 347–74.Google Scholar
  3. 3.
    Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of PC and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009, 301: 39–51.PubMedCentralPubMedGoogle Scholar
  4. 4.
    D’Amico A, Chen M, Roehl K, Catalona W. Preoperative PSA velocity and the risk of death from PC after radical prostatectomy. N Engl J Med 2004, 351: 125–35.PubMedGoogle Scholar
  5. 5.
    Roehrborn CG. Pathology of benign prostatic hyperplasia. Int J Impot Res 2008, 20(Suppl 3): S11–8.PubMedGoogle Scholar
  6. 6.
    Behre HM, Bohmeyer J, Nieschlag E. Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls. Clin Endocrinol (Oxf) 1994, 40: 341–9.Google Scholar
  7. 7.
    Huggins C, Hodges CV. Studies on prostatic cancer. The effect of castration, of estrogen and of androgen injection on serum phosphatase in metastatic carcinoma of the prostate. Cancer Res 1941, 1: 293–7.Google Scholar
  8. 8.
    Sharifi N. New agents and strategies for the hormonal treatment of castration-resistant prostate cancer. Expert Opin Investig Drugs 2010, 19: 837–46.PubMedGoogle Scholar
  9. 9.
    Shah S, Ryan C. Abiraterone acetate for castration resistant prostate cancer. Expert Opin Investig Drugs 2010, 19: 563–70.PubMedGoogle Scholar
  10. 10.
    Laufer M, Denmeade SR, Sinibaldi VJ, Carducci MA, Eisenberger MA. Complete androgen blockade for prostate cancer: what went wrong? J Urol 2000, 164: 3–9.PubMedGoogle Scholar
  11. 11.
    Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999, 17: 3461–7.PubMedGoogle Scholar
  12. 12.
    Page ST, Lin DW, Mostaghel EA, et al. Persistent intraprostatic androgen concentrations after medical castration in healthy men. J Clin Endocrinol Metab 2006, 91: 3850–6.PubMedGoogle Scholar
  13. 13.
    Wilson JD. Recent studies on the mechanism of action of testosterone. N Engl J Med 1972, 287: 1284–91.PubMedGoogle Scholar
  14. 14.
    Zhu YS, Imperato-McGinley JL. 5alpha-reductase isozymes and androgen actions in the prostate. Ann NY Acad Sci 2009, 1155: 43–56.PubMedGoogle Scholar
  15. 15.
    Raynaud JP. Prostate cancer risk in testosterone-treated men. J Steroid Biochem Mol Biol. 2006, 102: 261–6.PubMedGoogle Scholar
  16. 16.
    Gravas S, Oelke M. Current status of 5alpha-reductase inhibitors in the management of lower urinary tract symptoms and BPH. World J Urol 2010, 28: 9–15.PubMedCentralPubMedGoogle Scholar
  17. 17.
    Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of PC. N Engl J Med 2003, 349: 215–24.PubMedGoogle Scholar
  18. 18.
    Andriole GL, Bostwick DG, Brawley OW et al; REDUCE Study Group. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010, 362: 1192–202.PubMedGoogle Scholar
  19. 19.
    Strope SA, Andriole GL. Update on chemoprevention for prostate cancer. Curr Opin Urol 2010, 20: 194–7.PubMedGoogle Scholar
  20. 20.
    Walsh PC. Chemoprevention of prostate cancer. N Engl J Med 2010, 362: 1237–8.PubMedGoogle Scholar
  21. 21.
    Adorini L, Penna G, Fibbi B, Maggi M. Vitamin D receptor agonists target static, dynamic, and inflammatory components of benign prostatic hyperplasia. Ann NY Acad Sci 2010, 1193: 146–52.PubMedGoogle Scholar
  22. 22.
    Crescioli C, Ferruzzi P, Caporali A, et al. Inhibition of spontaneous and androgen-induced prostate growth by a nonhypercalcemic calcitriol analog. Endocrinology 2003, 144: 3046–57.PubMedGoogle Scholar
  23. 23.
    Morgentaler A, Traish AM. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol 2009, 55: 310–21.PubMedGoogle Scholar
  24. 24.
    Corona G, Boddi V, Lotti F, et al. The relationship of testosterone to prostate-specific antigen in men with sexual dysfunction. J Sex Med 2010, 7: 284–92.PubMedGoogle Scholar
  25. 25.
    Wu FC, Tajar A, Beynon JM, et al; EMAS Group. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 2010, 363: 123–35.PubMedGoogle Scholar
  26. 26.
    Gacci M, Corona G, Apolone G, et al. Influence of serum testosterone on urinary continence and sexual activity in patients undergoing radical prostatectomy for clinically localized prostate cancer. Prostate Cancer Prostatic Dis 2010, 13: 168–72.PubMedCentralPubMedGoogle Scholar
  27. 27.
    Takizawa I, Nishiyama T, Hara N, Isahaya E, Hoshii T, Takahashi K. Serum prostate-specific antigen levels reflect the androgen milieu in patients with localized prostate cancer receiving androgen deprivation therapy: Tumor malignant potential and androgen milieu. Prostate 2010, 70: 1395–401.PubMedGoogle Scholar
  28. 28.
    van Aubel OG, Bolt-de Vries J, Blankenstein MA, de Jong FH, Schröder FH. Circulating testosterone, prostatic nuclear androgen receptor and time to progression in patients with metastatic disease of the prostate treated by orchiectomy. Urol Res 1989, 17: 99–102.PubMedGoogle Scholar
  29. 29.
    Sher DJ, Mantzoros C, Jacobus S, Regan MM, Lee GS, Oh WK. Absence of relationship between steroid hormone levels and prostate cancer tumor grade. Urology 2009, 73: 356–61.PubMedGoogle Scholar
  30. 30.
    Travis RC, Key TJ, Allen NE, et al. Serum androgens and prostate cancer among 643 cases and 643 controls in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 2007, 121: 1331–8.PubMedGoogle Scholar
  31. 31.
    Folkerd EJ, Dowsett M. Influence of sex hormones on cancer progression. J Clin Oncol 2010, 28: 4038–44.PubMedGoogle Scholar
  32. 32.
    Roddam AW, Allen NE, Appleby P, Key TJ; Endogenous Hormones and Prostate Cancer Collaborative Group. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst 2008, 100: 170–83.PubMedGoogle Scholar
  33. 33.
    Fernández-Balsells MM, Murad MH, Lane M, et al. Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2010, 95: 2560–75.PubMedGoogle Scholar
  34. 34.
    Marks LS, Mazer NA, Mostaghel E, et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA 2006, 296: 2351–61.PubMedGoogle Scholar
  35. 35.
    Lindström S, Ma J, Altshuler D, et al. A large study of androgen receptor germline variants and their relation to sex hormone levels and prostate cancer risk. Results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. J Clin Endocrinol Metab 2010, 95: E121–7.PubMedCentralPubMedGoogle Scholar
  36. 36.
    Severi G, Morris HA, MacInnis RJ, et al. Circulating steroid hormones and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006, 15: 86–91.PubMedGoogle Scholar
  37. 37.
    Sofikerim M, Eskicorapci S, Oruç O, Ozen H. Hormonal predictors of prostate cancer. Urol Int 2007, 79: 13–8.PubMedGoogle Scholar
  38. 38.
    Massengill JC, Sun L, Moul JW, et al. Pretreatment total T level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol 2003, 169: 1670–5.PubMedGoogle Scholar
  39. 39.
    Imamoto T, Suzuki H, Fukasawa S, et al. Pretreatment serum T level as a predictive factor of pathological stage in localized prostate cancer patients treated with radical prostatectomy. Eur Urol 2005, 47: 308–12.PubMedGoogle Scholar
  40. 40.
    Isom-Batz G, Bianco FJ Jr, Kattan MW, Mulhall JP, Lilja H, Eastham JA. T as a predictor of pathological stage in clinically localized prostate cancer. J Urol 2005, 173: 1935–7.PubMedCentralPubMedGoogle Scholar
  41. 41.
    Morgentaler A, Rhoden EL. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less. Urology 2006, 68: 1263–7.PubMedGoogle Scholar
  42. 42.
    Isbarn H, Pinthus JH, Marks LS, et al. Testosterone and prostate cancer: revisiting old paradigms. Eur Urol 2009, 56: 48–56.PubMedGoogle Scholar
  43. 43.
    Eikenberry SE, Nagy JD, Kuang Y. The evolutionary impact of androgen levels on prostate cancer in a multi-scale mathematical model. Biol Direct 2010, 5: 24.PubMedCentralPubMedGoogle Scholar
  44. 44.
    Iversen P, Rasmussen F, Christensen IJ. Serum T as a prognostic factor in patients with advanced prostatic carcinoma. Scand J Urol Nephrol Suppl 1994, 157: 41–7.PubMedGoogle Scholar
  45. 45.
    Kaufman JM, Graydon RJ. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol 2004, 172: 920–2.PubMedGoogle Scholar
  46. 46.
    Agarwal PK, Oefelein MG. Testosterone replacement therapy after primary treatment for prostate cancer. J Urol 2005, 173: 533–6.PubMedGoogle Scholar
  47. 47.
    Khera M, Grober ED, Najari B, et al. Testosterone replacementtherapy following radical prostatectomy. J Sex Med 2009, 6: 1165–70.PubMedGoogle Scholar
  48. 48.
    Leibowitz RL, Dorff TB, Tucker S, Symanowski J, Vogelzang NJ. Testosterone replacement in prostate cancer survivors with hypogonadal symptoms. BJU Int 2010, 105: 1397–401.PubMedGoogle Scholar
  49. 49.
    Davilla H, Arison C, Hall M, Salup R, Lockhart J, Carrion R. Analysis of the PS Aresponse after testosterone supplementation in patients who previously received management for their localized prostate cancer. J Urol Suppl 2008, 179(Suppl 4): 428 (abs. 1247).Google Scholar
  50. 50.
    Nabulsi O, Tal R, Gotto G, Narus J, Goldenberg L, Mulhall JP. Outcomes analysis of testosterone supplementation in hypogonadal men following radical prostatectomy. J Urol Suppl 2008, 179(Suppl 4): 406 (abs. 1244).Google Scholar
  51. 51.
    Morales A, Black AM, Emerson LE. Testosterone administration to men with testosterone deficiency syndrome after external beam radiotherapy for localized prostate cancer: preliminary observations. BJU Int 2009, 103: 62–4.PubMedGoogle Scholar
  52. 52.
    Sarosdy MF. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer 2007, 109: 536–41.PubMedGoogle Scholar
  53. 53.
    Wang C, Nieschlag E, Swerdloff R, et al. International Society of Andrology (ISA); International Society for the Study of Aging Male (ISSAM); European Association of Urology (EAU); European Academy of Andrology (EAA); American Society of Andrology (ASA). Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. J Androl 2009, 30: 1–9.PubMedGoogle Scholar
  54. 54.
    Buvat J, Maggi M, Gooren L, et al. Endocrine aspects of male sexual dysfunctions. J Sex Med 2010, 7: 1627–56.PubMedGoogle Scholar
  55. 55.
    Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer 2005; 103: 1615–24.PubMedGoogle Scholar
  56. 56.
    Smith MR. Androgen deprivation therapy for prostate cancer: new concepts and concerns. Curr Opin Endocrinol Diabetes Obes 2007, 14: 247–54.PubMedCentralPubMedGoogle Scholar
  57. 57.
    Isbarn H, Boccon-Gibod L, Carroll PR, et al. Androgen Deprivation Therapy for the treatment of prostate cancer: consider both benefits and risks. Eur Urol 2009, 55: 62–75.PubMedCentralPubMedGoogle Scholar
  58. 58.
    Shahani S, Braga-Basaria M, Basaria S. Androgen Deprivation Therapy in prostate cancer and metabolic risk for atherosclerosis. J Clin Endocrinol Metab 2008, 93: 2042–9.PubMedGoogle Scholar
  59. 59.
    Saylor PJ, Smith MR. Metabolic complications of Androgen Deprivation Therapy for prostate cancer. J Urol 2009, 181: 1998–2008.PubMedCentralPubMedGoogle Scholar
  60. 60.
    Basaria S. Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth. J Androl 2008, 29: 534–9.PubMedGoogle Scholar
  61. 61.
    Serpa Neto A, Tobias-Machado M, Esteves MA, et al. Asystematic review and meta-analysis of bone metabolism in prostate adenocarcinoma. BMC Urol 2010, 10: 9.PubMedCentralPubMedGoogle Scholar
  62. 62.
    Brufsky AM. Cancer treatment-induced bone loss: pathophysiology and clinical perspectives. Oncol 2008, 13: 187–95.Google Scholar
  63. 63.
    Basaria S, Lieb J 2nd, Tang A, et al. Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol (Oxf) 2002, 56: 779.Google Scholar
  64. 64.
    Smith JC, Bennett S, Evans LM, et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 2001, 86: 4261–7.PubMedGoogle Scholar
  65. 65.
    Smith MR, Finkelstein JS, McGovern FJ, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 2002, 87: 599–603.PubMedGoogle Scholar
  66. 66.
    Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 2006, 91: 1305.PubMedGoogle Scholar
  67. 67.
    Chen Z, Maricic M, Nguyen P, Ahmann FR, Bruhn R, Dalkin BL. Low bone density and high percentage of body fat among men who were treated with androgen deprivation therapy for prostate carcinoma. Cancer 2002, 95: 2136–44.PubMedGoogle Scholar
  68. 68.
    Lee H, McGovern K, Finkelstein J, Smith MR. Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma. Cancer 2005, 104: 1633–7.PubMedGoogle Scholar
  69. 69.
    Corona G, Mannucci E, Forti G, Maggi M. Hypogonadism, ED, metabolic syndrome and obesity: a pathological link supporting cardiovascular diseases. Int J Androl 2009, 32: 587–98.PubMedGoogle Scholar
  70. 70.
    Traish AM, Guay A, Feeley R, Saad F. The dark side of testosterone deficiency: I. Metabolic syndrome and erectile dysfunction. J Androl 2009, 30: 10–22.PubMedGoogle Scholar
  71. 71.
    Corona G, Rastrelli G, Vignozzi L, Mannucci E, Maggi M. Testosterone, cardiovascular disease and the metabolic sindrome. Best Pract Res Clin Endocrinol Metab 2011, 25: 337–53.PubMedGoogle Scholar
  72. 72.
    Segal RJ, Reid RD, Courneya KS, et al. Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol 2003, 21: 1653.PubMedGoogle Scholar
  73. 73.
    Corona G, Monami M, Rastrelli G, et al. Type 2 diabetes mellitus and testosterone: a meta-analysis study. Int J Androl 2010, Oct 24. doi: 10.1111/j.1365-2605.2010.01117.x. [Epub ahead of print]Google Scholar
  74. 74.
    Ding EL, Song Y, Malik VS, Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2006, 295: 1288–99.PubMedGoogle Scholar
  75. 75.
    Pitteloud N, Mootha VK, Dwyer AA, et al. Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. Diabetes Care 2005, 28: 1636–42.PubMedGoogle Scholar
  76. 76.
    Muller M, Grobbee DE, den Tonkelaar I, Lamberts SW, van der Schouw YT. Endogenous sex hormones and metabolic syndrome in aging men. J Clin Endocrinol Metab 2005, 90: 2618–23.PubMedGoogle Scholar
  77. 77.
    Yialamas MA, Dwyer AA, Hanley E, Lee H, Pitteloud N, Hayes FJ. Acute sex steroid withdrawal reduces insulin sensitivity in healthy men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2007, 92: 4254–9.PubMedGoogle Scholar
  78. 78.
    Dockery F, Bulpitt CJ, Agarwal S, Donaldson M, Rajkumar C. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (Lond) 2003, 104: 195–201.Google Scholar
  79. 79.
    Basaria S, Muller DC, Carducci MA, Egan J, Dobs AS. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen deprivation therapy. Cancer 2006, 106: 581–8.PubMedGoogle Scholar
  80. 80.
    Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006, 24: 4448–56.PubMedGoogle Scholar
  81. 81.
    Moorjani S, Dupont A, Labrie F, et al. Changes in plasma lipoproteins during various androgen suppression therapies in men with prostatic carcinoma: effects of orchiectomy, estrogen, and combination treatment with luteinizing hormone-releasing hormone agonist and flutamide. J Clin Endocrinol Metab 1988, 66: 314–22.PubMedGoogle Scholar
  82. 82.
    Braga-Basaria M, Muller DC, Carducci MA, Dobs AS, Basaria S. Lipoprotein profile in men with prostate cancer undergoing androgen deprivation therapy. Int J Impot Res 2006, 18: 494–8.PubMedGoogle Scholar
  83. 83.
    Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 2007, 110: 1493–500.PubMedGoogle Scholar
  84. 84.
    D’Amico AV, Denham JW, Crook J, et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 2007, 25: 2420–5.PubMedGoogle Scholar
  85. 85.
    Tsai HK, D’Amico AV, Sadetsky N, Chen MH, Carroll PR. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 2007, 99: 1516–24.PubMedGoogle Scholar
  86. 86.
    Efstathiou JA, Bae K, Shipley WU, et al. Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02. Eur Urol 2008, 54: 816.PubMedGoogle Scholar
  87. 87.
    Roach M 3rd, Bae K, Speight J, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol 2008, 26: 585.PubMedGoogle Scholar
  88. 88.
    Efstathiou JA, Bae K, Shipley WU, et al. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol 2009, 27: 92.PubMedCentralPubMedGoogle Scholar
  89. 89.
    Studer UE, Whelan P, Albrecht W, et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol 2006, 24: 1868–76.PubMedGoogle Scholar
  90. 90.
    Nanda A, Chen MH, Braccioforte MH, Moran BJ, D’Amico AV. Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA 2009, 302: 866–73.PubMedGoogle Scholar
  91. 91.
    Hayes JH, Chen MH, Moran BJ, et al. Androgen-suppression therapy for prostate cancer and the risk of death in men with a history of myocardial infarction or stroke. BJU Int 2010, 106: 979–85.PubMedGoogle Scholar
  92. 92.
    Goldstein AS, Huang J, Guo C, Garraway IP, Witte ON. Identification of a cell of origin for human prostate cancer. Science 2010, 329: 568–71.PubMedCentralPubMedGoogle Scholar
  93. 93.
    Bostwick DG, Shan A, Qian J, et al. Independent origin of multiple foci of prostatic intraepithelial neoplasia: comparison with matched foci of prostate carcinoma. Cancer 1998, 83: 1995–2002.PubMedGoogle Scholar
  94. 94.
    Craft N, Chhor C, Tran C, et al. Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Res 1999, 59: 5030–6.PubMedGoogle Scholar
  95. 95.
    Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004, 10: 33–9.PubMedGoogle Scholar
  96. 96.
    Marques RB, van Weerden WM, Erkens-Schulze S, et al. The human PC346 xenograft and cell line panel: a model system for prostate cancer progression. Eur Urol 2006, 49: 245–57.PubMedGoogle Scholar
  97. 97.
    Zhou JR, Yu L, Zerbini LF, Libermann TA, Blackburn GL. Progression to androgen-independent LNCaP human prostate tumors: cellular and molecular alterations. Int J Cancer 2004, 110: 800–6.PubMedCentralPubMedGoogle Scholar
  98. 98.
    Visakorpi T, Hyytinen E, Koivisto P, et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995, 9: 401–6.PubMedGoogle Scholar
  99. 99.
    Koivisto P, Kononen J, Palmberg C, et al. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 1997, 57: 314–9.PubMedGoogle Scholar
  100. 100.
    Marcelli M, Ittmann M, Mariani S, et al. Androgen receptor mutations in prostate cancer. Cancer Res 2000, 60: 944–9.PubMedGoogle Scholar
  101. 101.
    Gregory CW, He B, Johnson RT, et al. Amechanism forandrogen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 2001, 61: 4315–9.PubMedGoogle Scholar
  102. 102.
    Locke JA, Guns ES, Lubik AA, et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 2008, 68: 6407–15.PubMedGoogle Scholar
  103. 103.
    Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008, 68: 4447–54.PubMedCentralPubMedGoogle Scholar
  104. 104.
    Hofland J, van Weerden WM, Dits NF, et al. Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer. Cancer Res 2010, 70: 1256–64.PubMedGoogle Scholar
  105. 105.
    Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TM-PRSS2 and ETS transcription factor genes in prostate cancer. Science 2005, 310: 644–8.PubMedGoogle Scholar
  106. 106.
    Mackinnon AC, Yan BC, Joseph LJ, Al-Ahmadie HA. Molecularbiology underlying the clinical heterogeneity of prostate cancer: an update. Arch Pathol Lab Med 2009, 133: 1033–40.PubMedGoogle Scholar
  107. 107.
    Baldi E, Bonaccorsi L, Nesi G, Serni S, Forti G, Luzzatto L. TM-PRSS2:ERG fusion gene and androgen-ablation therapy in prostate cancer. Arch Pathol Lab Med 2010, 134: 964–5.PubMedGoogle Scholar
  108. 108.
    Baldi E, Bonaccorsi L, Forti G. Androgen receptor: good guy or bad guy in prostate cancer invasion? Endocrinology 2003, 144: 1653–5.PubMedGoogle Scholar
  109. 109.
    Niu Y, Chang TM, Yeh S, Ma WL, Wang YZ, Chang C. Differential androgen receptor signals in different cells explain why androgendeprivation therapy of prostate cancer fails. Oncogene 2010, 29: 3593–604.PubMedGoogle Scholar
  110. 110.
    Sarker D, Reid AH, Yap TA, de Bono JS. Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin Cancer Res 2009, 15: 4799–805.PubMedGoogle Scholar
  111. 111.
    Signoretti S, Montironi R, Manola J, et al. Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst 2000, 92: 1918–25.PubMedGoogle Scholar
  112. 112.
    Culig Z. Androgen receptor cross-talk with cell signalling pathways. Growth Factors 2004, 22: 179–84.PubMedGoogle Scholar
  113. 113.
    Alimonti A, Nardella C, Chen Z, et al. Anovel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis. J Clin Invest 2010, 120: 681–93.PubMedCentralPubMedGoogle Scholar
  114. 114.
    Vashchenko N, Abrahamsson PA. Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities. Eur Urol 2005, 47: 147–55.PubMedGoogle Scholar
  115. 115.
    Theodorescu D, Broder SR, Boyd JC, Mills SE, Frierson HF Jr. Cathepsin D and chromogranin A as predictors of long term disease specific survival after radical prostatectomy for localized carcinoma of the prostate. Cancer 1997, 80: 2109–19.PubMedGoogle Scholar
  116. 116.
    Weinstein MH, Partin AW, Veltri RW, Epstein JI. Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostatectomy. Hum Pathol 1996, 27: 683–7.PubMedGoogle Scholar
  117. 117.
    Jin RJ, Wang Y, Masumori N, et al. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice. Cancer Res 2004, 64: 5489–95.PubMedGoogle Scholar
  118. 118.
    Amorino GP, Parsons SJ. Neuroendocrine cells in prostate cancer. Crit Rev Eukaryot Gene Expr 2004,14: 287–300.PubMedGoogle Scholar
  119. 119.
    Marchiani S, Tamburrino L, Nesi G, et al. Androgen-responsive and -unresponsive prostate cancer cell lines respond differently to stimuli inducing neuroendocrine differentiation. Int J Androl 2010, 33: 784–93.PubMedGoogle Scholar
  120. 120.
    Niu Y, Altuwaijri S, Lai KP, et al. Androgen receptor is a tumor suppressor and proliferator in prostate cancer. Proc Natl Acad Sci USA 2008, 105: 12182–7.PubMedCentralPubMedGoogle Scholar
  121. 121.
    Niu Y, Altuwaijri S, Yeh S, et al. Targeting the stromal androgen receptor in primary prostate tumors at earlier stages. Proc Natl Acad Sci USA 2008, 105: 12188–93.PubMedCentralPubMedGoogle Scholar
  122. 122.
    Bonaccorsi L, Carloni V, Muratori M, et al. Androgen receptor expression in prostate carcinoma cells suppresses alpha6beta4 integrin-mediated invasive phenotype. Endocrinology 2000, 141: 3172–82.PubMedGoogle Scholar
  123. 123.
    Bonaccorsi L, Carloni V, Muratori M, Formigli, et al. EGF receptor (EGFR) signaling promoting invasion is disrupted in androgen-sensitive prostate cancer cells by an interaction between EGFR and androgen receptor (AR). Int J Cancer 2004, 112: 78–86.PubMedGoogle Scholar
  124. 124.
    Bonaccorsi L, Nosi D, Muratori M, Formigli L, Forti G, Baldi E. Altered endocytosis of epidermal growth factor receptor in androgen receptor positive prostate cancer cell lines. J Mol Endocrinol 2007, 38: 51–66.PubMedGoogle Scholar
  125. 125.
    Cinar B, Koeneman KS, Edlund M, Prins GS, Zhau HE, Chung LW. Androgen receptor mediates the reduced tumor growth, enhanced androgen responsiveness, and selected target gene transactivation in a human prostate cancer cell line. Cancer Res 2001, 61: 7310–7.PubMedGoogle Scholar
  126. 126.
    Davis R, Jia D, Cinar B, et al. Functional androgen receptor confers sensitization of androgen-independent prostate cancer cells to anticancer therapy via caspase activation. Biochem Biophys Res Commun 2003, 309: 937–45.PubMedGoogle Scholar
  127. 127.
    Guerini V, Sau D, Scaccianoce E, et al. The androgen derivative 5alpha-androstane-3beta,17beta-diol inhibits prostate cancer cell migration through activation of the estrogen receptor beta subtype. Cancer Res 2005, 65: 5445–53.PubMedGoogle Scholar
  128. 128.
    Nightingale J, Chaudhary KS, Abel PD, et al. Ligand activation of the androgen receptor downregulates E-cadherin-mediated cell adhesion and promotes apoptosis of prostatic cancer cells. Neoplasia 2003, 5: 347–61.PubMedCentralPubMedGoogle Scholar
  129. 129.
    Berger R, Febbo PG, Majumder PK, et al. Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells. Cancer Res 2004, 64: 8867–75.PubMedGoogle Scholar
  130. 130.
    Zhu ML, Kyprianou N. Role of androgens and the androgen receptor in epithelial-mesenchymal transition and invasion of prostate cancer cells. FASEB J 2010, 24: 769–77.PubMedCentralPubMedGoogle Scholar
  131. 131.
    Kleeberger W, Bova GS, Nielsen ME, et al. Roles for the stem cell associated intermediate filament Nestin in prostate cancer migration and metastasis. Cancer Res 2007, 67: 9199–206.PubMedCentralPubMedGoogle Scholar
  132. 132.
    Debes JD, Tindall DJ. Mechanisms of androgen-refractory prostate cancer. N Engl J Med 2004, 351: 1488–90.PubMedGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 2011

Authors and Affiliations

  1. 1.Sexual Medicine and Andrology Unit, Department of Clinical PhysiopathologyUniversity of FlorenceFlorenceItaly
  2. 2.Endocrinology Unit, Medical Department, Azienda UslMaggiore-Bellaria HospitalBolognaItaly

Personalised recommendations